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ABSTRACT
Anthracyclines are key components of human breast cancer chemotherapy. Here, 
we explored the role of Akt signaling in anthracycline resistance.
The antitumor activity of doxorubicin and Akt inhibitor A-443654 alone or combined 
was examined in estrogen receptor (ER) positive and negative human breast cancer 
cell lines. Further, we examined mRNA changes induced by anthracyclines in locally 
advanced breast cancers biopsied before and after treatment in two clinical trials.
Doxorubicin increased Akt phosphorylation in ER positive MCF7 and T47D cell 
lines, with no effect in ER negative MDA-MB231 breast cancer cells. A-443654 was 
significantly more cytotoxic in doxorubicin-resistant compared to doxorubicin-naïve 
MCF7. This difference was not observed in MDA-MB231. Among 24 patients, AKT1 
gene expression increased 24 hrs after the initial epirubicin exposure in ER positive 
tumors responding to therapy (n=6), as compared to ER positive non-responders 
(n=7) or ER negative tumors (n=11). In contrast, AKT1 mRNA changes after 16 weeks 
of doxorubicin were unrelated to clinical response and ER status (n=30).
In conclusion, rapid Akt activation was observed in ER positive breast cancers 
which responded to anthracyclines. Increased cytotoxicity of A-443654 in doxorubicin-
resistant MCF7 cells indicates a possible role for Akt inhibitors in ER positive breast 
cancers where chemoresistance evolves.
INTRODUCTION
Phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K)-Akt-mammalian target of rapamycin (mTOR)-S6 
kinase (S6K) signaling (in short: PI3K signaling) is 
upregulated in 25% of human breast cancers and has been 
associated with resistance to endocrine as well as HER2 
directed therapy [1–3]. PIK3CA, encoding the p110α 
subunit of PI3K, harbors activating mutations in up to 45% 
of luminal A breast cancers [4], which are typically estrogen 
receptor (ER) positive tumors. Thus, therapeutic inhibition 
of the PI3K signaling pathway with the mTOR inhibitor 
everolimus can be used to counteract acquired resistance to 
aromatase inhibitors and prolong survival among patients 
with ER positive breast cancer [3]. Moreover, activating 
PIK3CA mutations are observed in ER negative breast 
cancer as well [4], and mTOR inhibition, combined with 
trastuzumab and paclitaxel, prolonged progression-free 
survival significantly among patients with hormone receptor 
negative, HER2 positive breast cancer [5]. However, the 
potential to treat chemoresistant breast cancer by inhibiting 
PI3K signaling has not been thoroughly addressed thus far.
Phosphatase and tensin homolog (PTEN) is the 
main endogenous inhibitor of PI3K activation [6]. While 
experimental studies revealed loss of PTEN function to 
be associated with reduced sensitivity to doxorubicin 
in breast and prostate cancer models, chemosensitivity 
was restored by concomitant mTOR inhibition [7, 8]. 
Furthermore, increased Akt phosphorylation is observed in 
doxorubicin-resistant ER positive, but not in ER negative 
breast cancer cell lines [9–11]. In line with this, inhibitors 
of the PI3K-Akt-mTOR pathway can be employed to 
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enhance anthracycline sensitivity in ER positive breast 
cancers [10, 11] Whereas the introduction of Akt inhibitors 
in clinical trials has been slower than PI3K and mTOR 
inhibitors [12], the key position of Akt as a signal hub for 
important pro-tumorigenic pathways [6] makes such trials 
highly relevant.
In the present work we assessed the influence of 
doxorubicin treatment on PTEN and Akt-mTOR-S6K 
signaling, and the interaction between doxorubicin and the 
Akt inhibitor A-443654 in ER positive and negative human 
breast cancer cell lines in vitro and in vivo. In particular, 
cell lines made resistant to doxorubicin by continous drug 
exposure were compared with doxorubicin-naïve cells to 
decipher the role of Akt-mTOR-S6K signaling in breast 
cancer chemoresistance. Furthermore, the short-term and 
long-term changes in PTEN and AKT1 gene expression 
subsequent to anthracycline exposure were assessed in 
patients with locally advanced breast cancers.
RESULTS
Influence of doxorubicin treatment on Akt 
activity and PI3K signaling in doxorubicin-naïve 
breast cancer cell lines
A sublethal concentration of doxorubicin (24 hrs 
exposure) was established by the WST-1 assay, to facilitate 
subsequent assessment of increased cytotoxicity when the 
A-443654 Akt inhibitor was introduced. The IC30 was 
approximately 1.5-2.0 μM for MB231 and MCF7 and 
0.5-1.0 μM for T47D (Supplementary Figure 1A). Based 
on this, doxorubicin was used at a concentration of 1.5 
μM for MB231, 2 μM for MCF7 and 0.7 μM for T47D 
for the in vitro experiments. Each experimental setup was 
conducted in three parallel cell cultures.
Doxorubicin increased phosphorylated Akt (p-Akt) 
in the ER positive MCF7 and T47D human breast cancer 
cell lines (Figure 1B, Supplementary Figure 1B). In 
contrast, p-Akt was not influenced by doxorubicin in 
the ER negative MB231 cell line (Figure 1A). Whereas 
doxorubicin had no impact on PTEN protein levels in 
neither cell line, mTOR phosphorylation levels increased 
in MB231 and decreased in MCF7 cells (Figure 1A-
1B), although not significant by densitometry (Figure 
1E-1F). Phosphorylated S6K was weakly expressed in 
both cell lines, and a non-significant decrease in S6K 
phosphorylation levels was observed in the MCF7 cell line 
after doxorubicin exposure (Figure 1A-1B).
AKT1 mRNA levels as determined by qPCR 
analysis remained unaltered 24 hours after doxorubicin 
exposure in all three cell lines (Supplementary Figure 2A). 
While PTEN mRNA levels decreased in MB231 cells, no 
change was observed in MCF7 and T47D cells subsequent 
to doxorubicin treatment (Supplementary Figure 2A). 
The reason why decreased PTEN mRNA levels did not 
translate into decreased PTEN protein levels in MB231 
cells exposed to doxorubicin remains to be elucidated, 
but the rapid changes in gene expression induced by 
the chemotherapy could take longer to translate into a 
change in protein levels, due to a half-life of more than 
8 hrs for PTEN [13]. Furthermore, there is no strong 
correlation between PTEN mRNA and PTEN protein 
levels in human breast cancer, which could be explained 
by post-transcriptional and post-translational mechanisms 
modifying protein expression and stability [14].
Influence of doxorubicin treatment on Akt 
activity and PI3K signaling in doxorubicin-
resistant cell lines
We performed the same experiments as outlined 
above in MB231 and MCF7 cells made resistant to 
doxorubicin through long-term doxorubicin exposure (see 
Methods & materials).
While doxorubicin exposure for 24 hours increased 
AKT1 gene expression in doxorubicin-resistant MCF7 
cells, no significant change in AKT1 expression was 
observed subsequent to doxorubicin expression in 
MB231 cells (Supplementary Figure 2B). Notably, 
PTEN gene expression was profoundly reduced 24 hrs 
after doxorubicin exposure in doxorubicin-resistant 
MB231, whereas a minor PTEN increase was observed 
in doxorubicin-resistant MCF7 cells (Supplementary 
Figure 2B). While p-Akt increased at the protein level 
in doxorubicin-resistant compared to doxorubicin-naïve 
MB231 cells, no change in downstream signaling was 
observed. The level of p-Akt was increased in doxorubicin-
resistant MB231 cells, compared to doxorubicin-naïve 
cells, but without any changes in downstream signaling 
(Figure 1A, 1C). In doxorubicin-resistant MCF7 cells, 
the protein levels of PTEN, p-Akt, mTOR and p-mTOR 
were higher compared to doxorubicin-naïve cells (Figure 
1B, 1D). However, an additional pulse of doxorubicin 
treatment did not change PTEN or Akt-mTOR-S6K 
protein levels further in doxorubicin-resistant MB231 or 
MCF7 cells, compared to sham treatment (Figure 1C-D).
Akt inhibition in doxorubicin-naïve and resistant 
MB231 and MCF7 cell lines
Next, we examined the cytotoxicity of the Akt 
inhibitor A-443654, alone or combined with doxorubicin, 
in the ER negative MB231 and ER positive MCF7 
cell lines. Moreover, based on the increased Akt 
phosphorylation levels observed in the doxorubicin-
resistant cell lines, we compared the doxorubicin-naïve 
and resistant cell lines with respect to Akt inhibitor 
cytotoxicity.
First, it was established that the IC30 concentration 
of A-443654 was 1.0 μM in MB231 and 0.5 μM in the 
MCF7 cell line (Supplementary Figure 2C). A-443654 is 
a known ATP competitive inhibitor of Akt, which causes 
a transient increase in Akt phosphorylation at S473 [15]. 
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In line with this, 2 hrs exposure to A-443654 increased 
Akt phosphorylation in a dose-dependent manner in 
MCF7 as well as MB231 cells (Figure 2A-2B). The 
induction of Akt by A-443654 in ER negative MB231 
cells was not influenced by doxorubicin resistance 
(Figure 2A). However, in ER positive MCF7 cells, 
the induction of Akt phosphorylation by A-443654 
was significantly less prominent in doxorubicin-
resistant compared to doxorubicin-naïve cells (Figure 
2B), suggesting that long-term doxorubicin exposure 
exhausts the ability to activate Akt and could influence 
the response to A-443654. Of notice, the baseline 
phosphorylation level of Akt in doxorubicin-naïve 
MB231 differed in Figure 1A and 2A, possibly due to 
the use of different dissolvents given to control cells 
in the two experiments; HPMC was used as dissolvent 
Figure 1: Doxorubicin treatment of doxorubicin-naïve and doxorubicin-resistant human breast cancer cell lines. (A-B) 
Western blots of PTEN and Akt-mTOR-S6K signaling in MB231 and MCF7 breast cancer cells in vitro, either doxorubicin-naïve (A-B) or 
doxorubicin-resistant (C-D, dox-res). Drug exposure lasted 24 hrs, at either 1.5 μM for MB231 and 2 μM for MCF7 or an equivalent volume 
of DMSO (stock solvent for doxorubicin) for control wells, three independent experiments per group. Whole cell lysate, 30 μg protein 
loaded per lane. (E-F) Densitometries for western blots (A-D) depict the relative protein expression, normalized to actin. Phosphorylated 
Akt (p-Akt) and mTOR (p-mTOR) were normalized to actin and thereafter to total Akt and mTOR, respectively. Bars represent the mean 
protein expression for experiments performed in triplicate ± SEM. **p<0.01
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Figure 2: Akt inhibitor treatment of doxorubicin-naïve and doxorubicin-resistant human breast cancer cell lines. (A-B) 
Western blots of Akt phosphorylation induced by increasing doses of the Akt inhibitor A-443654, 0-10 μM, 2 hrs exposure in doxorubicin-
naïve or doxorubicin-resistant MB231 (A) and MCF7 (B) human breast cancer cells in vitro. Whole cell lysate, 30 μg protein loaded per 
lane. Densitometries for western blots (A-B) depict the relative protein expression, normalized to actin and total Akt. Phosphorylated Akt 
increased significantly in doxorubicin-naïve (dox-naïve), compared to doxorubicin-resistant MCF7 cells (dox-res), at AKTi concentrations 
above 0.5 μM. *p<0.05. (C-D) Western blot analysis of Akt and downstream signaling in doxorubicin-naïve or doxorubicin-resistant MB231 
(C) and MCF7 (D) human breast cancer cells, after 24 hrs exposure to A-443654 (MB231: 1 μM, MCF7 0.5 μM) in vitro. Densitometries for 
western blots (C-D) depict the relative protein expression, normalized to actin. Bars represent the mean protein expression in experiments 
performed in triplicate ± SEM.
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for A-443654 (Figure 2A), whereas DMSO was the 
dissolvent for doxorubicin (Figure 1A).
To decipher the consequence of Akt inhibition in a 
wider time frame, Akt phosphorylation and downstream 
signaling was assessed after 24 hrs of A-443654 (IC30) 
exposure (Figure 2C-2D). As compared to 2 hrs, total 
Akt was profoundly reduced after 24 hrs, suggesting the 
Akt inhibitor may induce protein degradation. In parallel, 
phosphorylated Akt remained upregulated after 24 hrs 
of doxorubicin exposure in the doxorubicin-naïve as 
well as the doxorubicin-resistant MCF7 and MB231 cell 
lines, which is in accordance with the reported activity 
of A-443654 [16]. With respect to downstream signaling, 
it was clearly reduced by A-443654 in the doxorubicin-
naïve MCF7 cell line, with decreased GSK3 and S6K 
phosphorylation and increased 4EBP1 protein levels 
(Figure 2D), and the same signaling inhibition was 
observed in the doxorubicin-resistant MCF7 cell line. 
The influence of A-443654 on Akt downstream signaling 
was less pronounced in the MB231 cell line (Figure 
2C). Whereas reduced GSK3 and increased 4EBP1 
phosphorylation was observed in doxorubicin-naïve 
MB231, Akt inhibition had no influence on phosphorylated 
S6K. In doxorubicin-resistant MB231, A-443654 reduced 
S6K and increased 4EBP1 phosphorylation, in accordance 
with protein synthesis inhibition, but at the same time 
phosphorylated GSK3 protein levels increased, indicating 
glycogen synthase and cell cycle activation. All in all, 
these results point to a stronger dependence on Akt 
downstream signaling for cell proliferation in MCF7 than 
in MB231 breast cancer cells when doxorubicin resistance 
evolves.
Indeed, the Akt inhibitor exhibited significantly 
increased cytotoxicity in doxorubicin-resistant compared 
to doxorubicin-naïve MCF7 cells (Figure 3B). In contrast, 
the cytotoxicity of A-443654 was significantly reduced 
in doxorubicin-resistant compared to doxorubicin-naïve 
MB231 cells (Figure 3A). The cytotoxicity of A-443654 
was not augmented by doxorubicin in neither cell line 
(Figure 3A-3B).
Efficacy of doxorubicin and Akt inhibition in 
doxorubicin-naïve MB231 and MCF7 xenografts 
in vivo
The efficacy of sham treatment, A-443654 or 
doxorubicin, alone or in combination, was assessed 
in NOD/SCID mice implanted orthotopically with 
doxorubicin-naïve MB231 or MCF7 human breast cancer 
(n=5-6 mice/group).
The Akt inhibitor A-443654 was ineffective as 
monotherapy in MB231 tumors in mice, but inhibited 
tumor growth significantly in MCF7 tumors (Figure 
4A-4B). Doxorubicin treatment yielded significant 
tumor inhibition in both cancer subtypes. In MB231, 
the combination of doxorubicin and A-443654 inhibited 
tumor growth significantly compared to A-443654 or sham 
treatment, but only if A-443654 was postponed for a week 
after commencing doxorubicin administration (treatment 
group B). In contrast, co-administration of A-443654 
and chemotherapy (treatment group A) diminished the 
tumor growth inhibition induced by doxorubicin alone. 
In MCF7, the combination of doxorubicin and A-443654 
yielded significant tumor growth inhibition as compared to 
A-443654 or sham treatment, but only if the Akt inhibitor 
and doxorubicin were administered concomitantly 
(treatment group A). In both breast cancer models there 
was no significant difference in tumor response between 
doxorubicin alone and doxorubicin combined with 
A-443654.
Subcutaneous Akt inhibitor injections caused a 
7% weight loss after 14 days of treatment, which was 
comparable to combined treatment with doxorubicin and 
A-443654. However, the observed weight loss precluded 
further extension of the A-443654 treatment period, to 
assess whether long-term Akt inhibiton could augment 
the efficacy of doxorubicin. Unfortunately, two mice in 
the doxorubicin and one mouse in the doxorubicin and 
A-443654 group (A) had to be euthanized and taken out of 
the MCF7 trial due to accidental injection of doxorubicin 
into the gut wall and subsequent gut necrosis.
In a separate experiment, mice exposed to the 
same treatment regimens as above were euthanized 
after 14 days and tumor tissue extracted for molecular 
analysis (doxorubicin-naïve MB231; n=3 mice/
group and MCF7; n=2 mice/group). As monotherapy, 
A-443654 or doxorubicin yielded a heterogenous 
increase in Akt phosphorylation in MCF7 and to 
a lesser extent in MB231 xenografts, although not 
significant by densitometry (Figure 4C-4D). Combined 
treatment with A-443654 and doxorubicin increased 
Akt phosphorylation in MCF7 xenografts significantly, 
whereas the phosphorylation level of Akt in MB231 
was unaffected by the combination regimen (Figure 4C-
4D). While Akt phosphorylation increased substantially 
subsequent to 24 hours of A-443654 treatment in vitro 
(Figure 2A-2D), this increase was less pronounced 
in MB231 and MCF7 xenografts after two weeks of 
A-443654 treatment (Figure 4C-4D).
Potential effects of Akt inhibition was further 
monitored by analyzing downstream target effects (S6K 
phosphorylation status). In doxorubicin-naïve MB231 
tumors, protein analysis demonstrated significantly reduced 
S6K phosphorylation after treatment with doxorubicin alone 
or combined with A-443654 (Figure 4C). In doxorubicin-
naïve MCF7 tumors, A-443654 or doxorubicin, either 
alone or in combination, reduced mTOR phosphorylation 
(Figure 4D). Gene expression analysis of PTEN, AKT1 
and S6K in tumors extracted 14 days after commencing 
therapy (Supplementary Figure 3) demonstrated a 
significant decrease in AKT1 in MCF7 tumors subsequent 
to doxorubicin exposure, but apart from this no definite 
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differences between the treatment groups were observed in 
neither MCF7 nor MB231.
Gene expression changes induced by 
anthracyclines in human breast cancers
Next, to compare with the preclinical results, we 
examined how anthracyclines affected acute and chronic 
tumor gene expression by analyzing breast cancer samples 
obtained before and 24 hours after the first epirubicin 
(60 mg/m2 i.v.) course, or before and after 16 weeks 
of weekly doxorubicin (14 mg/m2 i.v.). All 24 tumors 
collected in the dose dense epirubicin trial (ClinicalTrials.
gov NCT00496795)expressed PTEN, AKT1 and S6K, 
before and/or after treatment (Supplementary Figure 4). 
Among the patients treated with epirubicin, AKT1 gene 
expression increased significantly (p=0.016) in tumors that 
subsequently regressed on treatment (PR; n=9), whereas 
no change was observed in tumors that did not respond 
(SD, PD; n=15, Figure 5A). The mRNA levels of PTEN 
and S6K did not change significantly, neither among 
responders nor non-responders (Figure 5A). Stratifying 
patients according to ER status, neither AKT1, PTEN nor 
S6K mRNA levels were influenced by epirubicin exposure 
among ER negative tumors (n=11), independent of clinical 
response to therapy (Figure 5B). Interestingly, among the 
ER positive tumors (n=13), AKT1 (p=0.040) as well as 
PTEN levels (p=0.039) increased significantly in patients 
who responded to therapy (n=6); whereas no change 
in neither AKT1 nor PTEN levels was observed among 
the non-responders (n=7, Figure 5B). Furthermore, S6K 
decreased significantly (p=0.027) in ER positive tumors 
that did not respond to therapy (n=7, Figure 5B).
After a median follow-up of 69 months, six out 
of 24 patients from the dose dense trial had developed 
breast cancer recurrence; no difference in gene expression 
changes between patients relapsing and those not relapsing 
was observed (Supplementary Figure 4).
To assess potential long-term effects of 
anthracycline treatment, tumor samples collected from 30 
patients with locally advanced breast cancers, before and 
after 16 weeks of doxorubicin [30, 31], were examined for 
long-term gene expression changes of PTEN and AKT1 
(Supplementary Figure 5). Analysing all patients together, 
no change in neither AKT1 nor PTEN expression was 
observed. However, stratifying patients based on response 
to therapy, PTEN expression increased significantly 
(p=0.033) among non-responders (patients having a PD 
or SD on therapy; n=17), in particular among ER negative 
non-responders (n=4; p=0.026; Figure 6A-6B). In contrast, 
Figure 3: Cytotoxicity of A-443654 and doxorubicin in doxorubicin-naïve and doxorubicin-resistant human breast 
cancer cell lines. In vitro cytotoxicity of doxorubicin (1 μM), Akt inhibitor A-443654 at IC30 concentration, or the combination, in 
doxorubicin-naïve or resistant MB231 (A) and MCF7 (B) cells, after 24 hrs drug exposure. WST-1 cell proliferation assay, absorbance 
read at optical density (OD) 450 nm, normalized to readings in control wells exposed to equivalent volumes of DMSO (doxorubicin stock 
solvent) and HPMC (dissolvent for A-443654). Bars depict the mean ± SEM.**p<0.01, ***p<0.001
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Figure 4: The influence of A-443654 and doxorubicin on tumor growth in vivo. (A-B) Tumor growth of MB231 and MCF7 
breast cancer in NOD/SCID mice, given doxorubicin (DOX) 1.25 mg/kg i.p. qW twice (red arrows), Akt inhibitor A-443654 (AKTi) 3.75 
mg mg/kg BID 14 days (green lines) or the combination. AKTi treatment commenced either at the first (A) or at the second (B) doxorubicin 
injection. Tumor volume is displayed as the mean ± SEM for each group, relative to tumor volume on the day treatment started. *p<0.05, 
**p<0.01. (C-D) Western blots for PTEN and Akt-mTOR-S6K signaling in MB231 (C) and MCF7 (D) tumors, harvested the last day of 
A-443654 treatment. Whole cell lysate, 30 μg protein loaded per lane. The sample order on the blot pictures has been rearranged to enhance 
readability. Densitometries for western blots (C-D) depict the relative protein expression, normalized to actin. Phosphorylated Akt (p-Akt) 
and mTOR (p-mTOR) were normalized to actin and thereafter to total Akt and mTOR, respectively. Bars represent the mean protein 
expression for experiments performed in duplicate (D) or triplicate (C) ± SEM. *p<0.05
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while 22 out of 30 patients had relapsed during a median 
follow-up of 235 months, gene expression changes did not 
correlate to long-term outcome (Supplementary Figure 5).
The mutation status of PIK3CA and TP53 was 
assessed in all the above tumor samples (Supplementary 
Figure 4 and Supplementary Figure 5). The low number 
of tumors harboring PIK3CA mutations precluded any 
correlation analysis between PIK3CA mutation status 
and the gene expression changes observed. Among 
tumors assessed before and 24 hours after the initial 
epirubicin course, no difference in PTEN or AKT1 
gene expression was observed regardless of response to 
Figure 5: AKT1, PTEN and S6K gene expression in human breast cancers before and 24 hrs after epirubicin exposure. 
(A) Box plots of gene expression of PTEN, AKT1 and S6K normalized to RPLP2 in human breast cancer samples, before and 24 hrs after 
the first epirubicin dose, from patients in the dose dense trial. (B) Box plots from the same patient cohort as in (A), but depicted separately 
for estrogen receptor (ER) positive and ER negative breast cancers. *p<0.05
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Figure 6: AKT1 and PTEN gene expression in human breast cancers before and after 16 weeks of doxorubicin 
treatment. (A) Box plots of gene expression of PTEN and AKT1 normalized to RPLP2 in human breast cancer samples, before and after 
16 weeks of doxorubicin treatment, from patients in the doxorubicin trial. (B) Box plots from the same patient cohort as in (A), but depicted 
separately for estrogen receptor (ER) positive and negative breast cancers. *p<0.05
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chemotherapy, if subdivided into TP53 wt (n=16) and 
TP53 mutated tumors (n=8). Upregulated AKT1 24 hrs 
after the first epirubicin exposure was observed in six 
out of 13 ER positive breast cancers which subsequently 
regressed on this treatment (Figure 5); and four out of 
these six tumors where AKT1 increased harbored wt 
TP53 status (Supplementary Figure 4).
In tumors examined before and after 16 wks of 
doxorubicin, if split by TP53 mutation status (TP53 
wt; n=15, TP53 mutated; n=15), PTEN increased 
significantly after treatment (p=0.02) in tumors harboring 
TP53 mutations that did not respond to doxorubicin 
treatment (n=8), whereas no change was observed among 
responders (n=7) or among TP53 wt tumors (data not 
shown). Also, there was no significant change in AKT1, 
among responders or non-responders to doxorubicin, if the 
subgroups were split by TP53 mutation status.
DISCUSSION
Patients with ER positive as well as ER negative 
breast cancer obtain improved survival from adjuvant 
polychemotherapy [17], but the benefit of chemotherapy is 
less in typical luminal A tumors with strong ER expression 
compared to other subtypes [18]. The mutational 
landscape of breast cancer subtypes differ substantially, 
with a high prevalence of activating PIK3CA mutations in 
ER positive, luminal or HER2-enriched tumors, whereas 
inactivating TP53 mutations are commonly observed in 
ER negative subtypes [4]. Moreover, while activating 
AKT1 mutations are rare in human breast cancers, they 
occur more frequently among luminal or HER2-enriched 
(2-4%) than basal-like tumors (0%) [4], suggesting a 
selection pressure towards increased Akt signaling in 
these neoplasms. Accordingly, the PI3K-Akt-mTOR 
pathway has been targeted therapeutically to counteract 
acquired resistance to endocrine therapy and combined 
trastuzumab-chemotherapy in clinical trials [1, 3, 5, 19]. 
However, the importance of PI3K-Akt-mTOR signaling to 
chemoresistance has not been fully elucidated.
Here, we systematically explored alterations in this 
pathway in response to anthracycline and/or Akt inhibition 
in ER positive and negative breast cancer cell lines 
and their concomitant xenografts and to anthracycline 
treatment in human breast cancers.
We established that the Akt inhibitor A-443654 
reduces cell proliferation both in the ER positive MCF7 
and the ER negative MB231 cell line in vitro. However, 
Akt inhibition yielded tumor regression in MCF7 and not 
MB231 in vivo, and doxorubicin significantly augmented 
this tumor response only in MCF7 xenografts. Of notice, 
A-443654 caused significant weight loss which was 
intolerable beyond 14 days, and we therefore could 
not explore its full potential alone or combined with 
anthracyclines. Toxicity was a similar problem in the first 
clinical trials testing Akt inhibitors, although next generation 
compounds seem better tolerated [20] and should be tested 
in long-term combination schedules with anthracyclines. 
Importantly, the combined efficacy of A-443654 and 
doxorubicin was dependent on timing, where concomitant 
administration of the Akt inhibitor and chemotherapy was 
required for optimal tumor regression in MCF7 xenografts. 
In contrast, co-administration of A-443654 with doxorubicin 
reduced the efficacy of doxorubicin in MB231 xenografts. 
Doxorubicin yielded rapid upregulation of phosphorylated 
Akt in MCF7 cells in vitro, whereas long-term exposure 
and induction of doxorubicin resistance was required 
to upregulate phosphorylated Akt in MB231. This may 
explain the different efficacy with respect to timing between 
doxorubicin and the Akt inhibitor in the two cell lines.
Previous studies have revealed A-443654 to act as 
an ATP competitive inhibitor of Akt; as such, it increases 
Akt phosphorylation while at the same time inhibiting Akt 
downstream signaling [15, 16]. Accordingly, A-443654 
rapidly increased Akt phosphorylation, which was more 
pronounced in the MCF7 as compared to the MB231 cell 
line, and suggesting a particular responsiveness of the PI3K-
Akt-mTOR pathway in ER positive breast cancer cells. 
However, the cytotoxicity of A-443654 was comparable 
between MCF7 and MB231, and similar inhibition of Akt 
downstream signaling was observed in the ER positive and 
ER negative cell lines. In contrast, the activity of A-443654 
was profoundly reduced in doxorubicin-resistant MB231 
cells, where the inhibition of Akt signaling by A-443654 was 
abrogated. Interestingly, doxorubicin resistance enhanced 
the cytotoxicity of A-443654 significantly in MCF7, with 
maintained inhibition of Akt downstream signaling. The 
mechanisms behind the enhanced activity of A-443654 in 
doxorubicin-resistant MCF7 cells remain to be established. 
However, the baseline Akt phosphorylation level is higher 
in the doxorubicin-resistant MCF7 cell line, as compared to 
doxorubicin-naïve MCF7 cells, potentially explaining the 
increased cytotoxicity towards A-443654.
In line with previous observations [10, 21], we 
established that doxorubicin exposure increases Akt 
phosphorylation in the ER positive MCF7 and T47D 
human breast cancer cell lines, but not the ER negative 
MB231 cell line. Herein we expand upon these data to 
show that MCF7 cells made resistant to doxorubicin 
exhibit a higher constitutive Akt phosphorylation levels 
which is not affected by further doxorubicin exposure. The 
increased cytotoxicity of Akt inhibition in doxorubicin-
resistant MCF7 breast cancer cells points to a potential 
use of such a drug class in ER positive breast cancer, in 
particular if resistance to anthracycline has developed 
and Akt phosphorylation levels are elevated. Importantly, 
while the Akt inhibitor exhibited increased cytotoxicity 
in doxorubicin-resistant compared to doxorubicin-naïve 
MCF7 breast cancer, we did not examine whether Akt 
inhibitors can be used to reverse doxorubicin resistance, 
but this issue should be addressed in future trials. 
However, upregulated PI3K-Akt-mTOR signaling is 
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clearly associated with chemoresistance, which has 
been shown in various preclinical cancer models, and 
chemotherapy response can be augmented in this setting 
by simultaneous PI3K or Akt inhibition [10, 11, 22–24], in 
particular in ER positive breast cancer [10, 22].
Finally, we provide clinical data demonstrating that 
increased AKT1 gene expression 24 hours after epirubicin 
exposure characterizes ER positive, but not ER negative, 
primary breast cancers that subsequently regress on 
anthracycline treatment. Interestingly, no change in tumor 
AKT1 expression was observed in patients after 16 weeks 
of doxorubicin, suggesting an intermittent Akt response 
where the efficacy of Akt inhibitors could depend on 
timing. Furthermore, an increased AKT1 mRNA level 24 
hrs after the first chemotherapy course could potentially 
be used as a biomarker identifying ER positive tumors 
likely to respond to chemotherapy. The reason why 
elevated AKT1 mRNA is associated with good response 
remains to be elucidated. However, if high AKT1 translates 
into increased Akt activation throughout the duration 
of chemotherapy, chronic Akt activation may promote 
senescence and apoptosis by downregulating MDM2 
and increasing p53 in breast cancers with preserved p53 
function [25, 26]. Of notice, among the ER positive 
breast cancers which responded to epirubicin, four out 
of six tumors with upregulated AKT1 after chemotherapy 
harbored wt TP53 status.
In contrast to the patient data, AKT1 mRNA levels 
were not affected in the MB231 and MCF7 human breast 
cancer cell lines after 24 hrs chemotherapy exposure. The 
reason for this discrepancy remains to be elucidated, but 
could be due to the admixture of tumor cells and stroma 
in patient tumor samples in contrast to the pure tumor cell 
content in the in vitro cultures. Unfortunately, we did not 
have patient samples available for proteinanalysis of Akt 
and Akt signaling to compare with the gene expression 
data. Furthermore, the induction of Akt phosphorylation 
by A-443654 which was observed in MB231 and MCF7 
in vitro, was not detected in the corresponding xenografts. 
Again, the admixture of tumor cells and stroma cells in 
vivo, as well as the heterogeneity between the xenografts 
may explain the lack of correlation between the in vivo 
and in vitro findings. Moreover, the xenografts used for the 
proteinanalysis were extracted after 14 days of treatment 
compared to the 2 hrs and 24 hrs of treatment in the in 
vitro experiments. The reason why decreased PTEN 
mRNA levels did not decrease PTEN protein levels in 
MB231 cells after 24 hrs exposure to doxorubicin also 
remains to be established. Whereas rapid changes in gene 
expression are induced by the chemotherapy, protein 
changes may take longer to develop due to the relatively 
long half-life of PTEN (>8 hrs) [13]. Furthermore, there 
is no strong correlation between PTEN mRNA and PTEN 
protein levels in human breast cancer [14], which could 
be explained by post-transcriptional and post-translational 
mechanisms modifying protein expression and stability.
In conclusion, our data point to upregulated Akt 
expression as a recurrent initial response to anthracyclines 
in ER positive human breast cancers, and in particular, 
among patients who respond to chemotherapy. 
Furthermore, we observed increased sensitivity to 
Akt inhibition in doxorubicin-resistant, compared to 
doxorubicin-naïve, ER positive MCF7 breast cancer 
cells. Accordingly, the benefit of Akt inhibition is clearly 
context-dependent, with respect to ER status and previous 
anthracycline exposure. Thus far, the role of Akt inhibitors 
to augment the efficacy of chemotherapy in solid tumors 
has not been dealt with to a large extent, despite promising 
preclinical and clinical data [23, 24, 27–29] and should 
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Cell lines
The ER positive MCF7 and T47D and the ER 
negative MDA-MB-231 (MB231) human breast cancer 
cell lines were used for all the preclinical experiments. 
For cell growth conditions and cell line identity, see 
Supplementary methods. Doxorubicin (Adriamycin, 
Pfizer) was diluted to 2 mg/ml in DMSO 99% for cell 
culture experiments, stored as frozen aliquots (-20°C), and 
prepared fresh by dilution in complete cell culture medium 
for each experiment to preserve drug stability. Control 
cells were always incubated with an equivalent volume 
of DMSO 99% as cells exposed to medium containing 
doxorubicin. A-443654 (AbbVie) was dissolved in 0.2% 
hydroxypropyl methylcellulose (HPMC, Sigma) prior 
to use. For comparison, control cells were given an 
equivalent volume of HPMC as those cells exposed to 
A-443654.
Generation of doxorubicin-resistant cell lines
Doxorubicin-naïve MB231 and MCF7 cells were 
grown in gradually increasing doxorubicin concentrations 
over several months. When the cells were subconfluent 
they were exposed to growth medium containing twice 
the previous concentration of doxorubicin, and this was 
repeated until a dose was reached, where the cells would 
not expand any further. At this point, the cells had acquired 
resistance to doxorubicin 1.5 μM (MB231 dox-res) and 
doxorubicin 0.65 μM (MCF7 dox-res), each by exposure 
for 48 hrs. The cells were maintained in doxorubicin-free 
medium, but exposed to doxorubicin at their resistance 
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dose every two weeks to maintain resistance. Control cells 
were propagated in medium with an equivalent volume of 
DMSO. To determine the acute response to doxorubicin in 
doxorubicin-resistant cells, the cells were seeded at 3x105 
in 6-well dishes (Nunc) and incubated for 24 hrs until 70% 
confluence. The medium was then replaced by medium 
containing either doxorubicin or DMSO, and cells were 
incubated for another 24 hrs before the cells was harvested 
and RNA and protein isolated.
In vitro activity and cytotoxicity of A-443654 and 
doxorubicin
Subconfluent MB231 and MCF7 cells (in T25 
flasks), either doxorubicin-naïve or doxorubicin-resistant, 
were exposed to increasing concentrations of Akt inhibitor 
A-443654 or HPMC (control) to assess the influence on 
Akt phosphorylation, and protein was harvested after 
2 hrs. To evaluate the influence of the Akt inhibitor on 
Akt phosphorylation and downstream signaling after 24 
hrs, cells were exposed to A-443654 at the IC30 (1 μM 
MB231, 0,5 μM MCF7), before harvesting protein.
To assess the influence of doxorubicin +/- Akt 
inhibitor A-443654 on cell viability, 5000 MB231, 1500 
MCF7 or 20000 T47D cells were seeded per well in 96-
well plates (Falcon), and allowed to attach over night 
in complete medium. Thereafter the drug(s) was added, 
before culturing the cells for another 24 hours. Cell 
proliferation after drug exposure was assessed by the 
WST-1 assay (Roche), as described in the manufacturer´s 
manual.
Gene expression analysis and western blots
Therapy-induced changes in gene and protein 
expression were assessed using qPCR and western blot 
analyses. Detailed methods, primers and antibodies are 
described in Supplementary methods.
In vivo cytotoxicity of A-443654 and doxorubicin
NOD/SCID mice were bred and mouse crossings 
performed inhouse at the Animal Facility, University of 
Bergen. Adult mice of fertile age were anesthetized with 
isoflurane (Baxter) before 1x106 MCF7 or MB231 cells were 
injected orthotopically in the fourth left inguinal mammary 
gland. The tumors were measured every 3-4 days using 
Vernier calipers, and tumor volumes were calculated using 
the formula a2b/2, where a and b are the shorter and longer 
diameter of the tumors respectively. Treatment commenced 
when the tumors had reached 4-6 mm in diameter, and 
the animals were stratified into groups according to tumor 
size. The mice were euthanized if signs of serious distress 
occurred or when the first tumor in any treatment group had 
a tumor diameter exceeding 17 mm.
The maximum tolerable dose (MTD) of doxorubicin, 
given weekly for two following weeks, with or without 
the Akt inhibitor A-443654 was initially assessed in non-
tumor bearing NOD/SCID mice before commencing the 
therapy trial in xenograft-implanted mice. Doxorubicin 
was dissolved in 0.9% NaCl (Baxter) and injected i.p. once 
weekly for two consecutive weeks to establish an MTD of 
1.25 mg/kg qW. A-443654 was dissolved in HPMC and 
administered subcutaneously at 3.75 mg/kg BID for 14 
consecutive days, based on dosage reported elsewhere 
[16]. In the combination treatment groups, administration 
of A-443654 commenced either upfront (A), 24 hours after 
the first doxorubicin injection (to treat primary resistance 
due to high Akt signaling), or started as a delayed regimen 
(B) at the same time as the second doxorubicin injection 
(to counteract doxorubicin-induced acquired resistance 
due to upregulated Akt signaling). Control mice were 
given 0.2% HPMC s.c. and 0.9% NaCl i.p.
In a separate experiment, three MB231 mice and 
two MCF7 mice per group were sacrificed at the end of 14 
days of treatment (as given in the treatment trial above) for 
protein analysis. All animals were euthanized by cervical 
dislocation two hours after the last injection of A-443654 
or sham treatment, and tissue samples from the tumor as 
well as all organs snap-frozen on liquid N2 and stored at 
-80°C.
The animal experiments were performed with the 
approval of and in accordance with guidelines by the 
Norwegian State Commission for Laboratory Animals.
Patient breast cancer samples
The short-term effect of anthracyclines on PTEN, 
AKT1 and S6K gene expression was assessed in a selected 
cohort of 14 ER positive and 11 ER negative breast 
cancers biopsied before and 24 hrs after receiving their 
first course of epirubicin as part of the “dose dense trial” 
(ClinicalTrials.gov NCT00496795) wherein treatment-
naïve patients with locally advanced breast cancer were 
given dose dense neoadjuvant epirubicin 60 mg/m2 q2w 
(four courses) followed by docetaxel 100 mg/m2 q2w 
(four courses). The presence of pre-treatment PIK3CA 
and TP53 mutations in all tumor samples were examined 
as described in Supplementary methods. One ER positive 
tumor pair was excluded due to poor RNA quality, leaving 
24 tumor pairs for analysis.
Furthermore, to analyze for long-term effects of 
anthracyclines on PTEN and AKT1 mRNA levels, gene 
expression was assessed in paired tumor samples from 
30 patients with treatment-naïve locally advanced breast 
cancer in the “doxorubicin trial”, biopsied before and 
after 16 wks of neoadjuvant doxorubicin 14 mg/m2 qW 
treatment [30, 31]. Briefly, tumor pairs for mRNA analysis 
were available from 24 patients with ER positive and six 
patients with ER negative locally advanced breast cancer.
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The dose dense and doxorubicin clinical trials 
were approved by the Regional Ethical Committee of the 
Western health region in Norway (reference numbers: 
192/91-69.91 and 079.06). All patients gave their informed 
consent before inclusion. Accordingly, all procedures 
performed in these clinical trials were in accordance with 
the national ethical standards and with the 1964 Helsinki 
declaration and its later amendments.
Statistics
SPSS 22/PASW 17.0 and Graph Pad Prism v6 
software packages were used for statistical analyses. 
Correlation analysis between AKT1 and PTEN or S6K 
mRNA expression levels was performed using Spearman´s 
rho. Comparison of gene or protein expression levels was 
performed using the Student’s t-test for paired samples 
or two independent samples, as appropriate. All p-values 
reported are two-tailed, and p<0.05 was considered 
statistically significant.
Availability of data and materials
All raw data generated from the experiments 
presented are available from the corresponding author 
upon request. The data subset used for mutational calling 
of TP53 and PIK3CA in the “dose dense trial” was 
extracted from whole exome sequencing data, and the 
DNA sequences are available from the corresponding 
author upon request.
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